search
for
 About Bioline  All Journals  Testimonials  Membership  News


Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 13, No. 4, 1996
Bioline Code: ba96102
Full paper language: English
Document type: Research Article
Document available free of charge

Biotecnologia Aplicada, Vol. 13, No. 4, 1996

 en High-dose Alpha-interferon Treatment in Amyotrophic Lateral Sclerosis
Farkkila, Markus; Laaksovirta, Hannu; Hokkanen, Laura & Cantell, Kari

Abstract

Twenty four patients with the spinal form of amyotrophic lateral sclerosis (ALS), 10 in an open series and 14 in a randomized placebo controlled manner, were treated with a short, single course of the maximum tolerated dose of natural alpha interferon. The drug was administered as a continuous intravenous infusion in the course of four to six days. The doses ranged between 250 and 950 million IU, (a mean of 560 IU). Such high-doses caused notable side-effects which were dose limiting; tiredness and fatigue up to unconsciousness were the most common. Reversible leukopenia was also observed. The mean survival time for interferon-treated patients (N = 19) was 42.6 months, and for placebo-treated patients (N = 5) 30.0 months. These results suggest that the maximum tolerated interferon dose was reached without a notable change in the course of ALS.

Keywords
maximum IFN dose

 
 es
Farkkila, Markus; Laaksovirta, Hannu; Hokkanen, Laura & Cantell, Kari

Resumen

Se trataron 24 pacientes con la forma espinal de esclerosis lateral amiotrofica (ALS), 10 en una serie abierta y 14 de forma aleatorizada, controlada, con un ciclo dnico, corto de la dosis maxima tolerable de interferon alfa natural. La droga se administro en una infusion intravenosa continua durante cuatro a seis dias. Las dosis estuvieron entre 250 y 950 millones de UI (promedio 560 millones UI). Dosis tan altas produjeron efectos secundarios notables, que fueron limitantes de la dosis. El cansancio y fatiga hasta la inconsciencia fueron los mas frecuentes, asi como leucopenia reversible. La supervivencia promedio de los pacientes que recibieron interferon (N = 19) fue de 42,6 meses y la de los que recibieron placebo (N = 5) fue de 30,0 meses. Los resultados sugieren que se alcanzo la dosis maxima tolerable de interferon sin un cambio notable en el curso de la ALS.

Palabras-clave
dosis maxima de IFN

 
© Copyright 1996 Elfos Scientiae
Alternative site location: http://elfosscientiae.cigb.edu.cu/Archivo.asp?Id=6

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil